Acquisition - January 27, 2020
AstraZeneca divests rights to hypertension medicines
AstraZeneca has agreed to sell the global commercial rights to Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs Pharma. The agreement excludes the rights in the US and India, which were previously divested, and in Japan, which will be retained by AstraZeneca. The medicines, used primarily to treat hypertension, have lost their patent protection globally. […]
Collaboration - January 22, 2020
AstraZeneca Young Health programme partners with UNICEF
AstraZeneca will support UNICEF with a $12.5 million grant to support programming which will reach more than five million young people, train 1,000 youth advocates, and positively shape public policy around the world, over the next six years. The announcement follows AstraZeneca’s decision in October 2019 to continue to fund its Young Health Programme to […]
Pharma Business - January 21, 2020
AstraZeneca’s Lynparza granted Priority Review in the US
AstraZeneca and MSD have announced that a supplemental New Drug Application for Lynparza (olaparib) has been accepted and granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have progressed following prior treatment with a new […]
Pharma Business - January 20, 2020
AstraZeneca’s Imfinzi and tremelimumab granted Orphan Drug designation in the US for liver cancer
Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. The US Food and Drug Administration (FDA) grants ODD to medicines intended for the treatment, diagnosis or prevention of […]
Clinical Trials - January 14, 2020
AstraZeneca closes its Phase III STRENGTH trial for Epanova
Following the recommendation from an independent Data Monitoring Committee, AstraZeneca has decided to close the Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) due to its low likelihood of demonstrating a benefit to patients with mixed dyslipidaemia (MDL) who are at increased risk of cardiovascular (CV) disease. STRENGTH is a large-scale, global CV outcomes trial designed […]
Pharma Business - January 14, 2020
AstraZeneca’s Lynparza granted Priority Review in the US
AstraZeneca’s Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer. AstraZeneca and MSD have announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted Priority Review in the US for the maintenance treatment of patients with […]
